Replies to post #16848 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE

This refers to my MNTA post dated - January 10, 2016

"High-resolution, Integrated Molecular Profiling Reveals Persistent Inflammation in Kawasaki disease Patients with Coronary Artery Aneurysms"
Date/Time: Friday, June 12, 2015 during the 10:30am-12:00pm CET session

As part of the Company's research on intravenous immunoglobulin (IVIG), Momenta applied its high-resolution biological analytics to identify biologies impacted by treatment, and biologies associated with clinical resolution of Kawasaki disease. This oral presentation describes Momenta's approach to identifying biomarkers associated with sub-clinical disease activity and provides insights into the mechanism of action of IVIG in this disease.